Sign Up Today and Learn More About PsiQuantum Stock
Invest in or calculate the value of your shares in PsiQuantum or other pre-IPO companies through EquityZen, part of Morgan Stanley.
PsiQuantum Stock (PSIQ)
PsiQuantum aims to leverage silicon photonics to build fault-tolerant quantum computers.
PsiQuantum focuses on building a large-scale, general-purpose silicon photonic quantum computer with at least 1 million physical qubits.
About PsiQuantum Stock
Founded
2016
Headquarters
Palo Alto, CA, US
Total Funding
1.8B
Industries
Hardware, Software, Science and Engineering
PsiQuantum is focused on developing and deploying utility-scale, fault-tolerant quantum computers by leveraging silicon-photonics and advanced semiconductor manufacturing. The company claims to be building wafers of quantum chips, testing production cryogenic cabinets, and optimizing quantum algorithms. PsiQuantum acknowledges its commitment to serving as a government partner, while applying the technology to sectors like sustainability, healthcare, finance, transportation, and security.
PsiQuantum Press Mentions
Stay in the know about the latest news on PsiQuantum
PsiQuantum Appoints Niklas Zennström to Board of Directors
morningstar • Aug 11, 2026
PsiQuantum lands $125m DARPA quantum deal
eenewseurope • Jul 25, 2026
PsiQuantum lands $125M federal quantum computing deal
bizjournals • Jul 23, 2026
Quantum computing startup PsiQuantum signs $125 million DARPA deal
marketscreener • Jul 22, 2026
PsiQuantum has a plan to make a massive quantum computer out of light
technologyreview • Jul 15, 2026
Investors in PsiQuantum
Discover investors in PsiQuantum stock and explore their portfolio companies
PsiQuantum Management
Leadership team at PsiQuantum
Chief Executive Officer
Victor Peng
Co-founder and Chief Scientific Officer
Peter Shadbolt
Join now and verify your accreditation status to gain access to:
- PsiQuantum Current Valuation
- PsiQuantum Stock Price
- PsiQuantum Management
- Available deals in PsiQuantum and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- PsiQuantum Cap Table and Funding History by Share Class and Liquidity Preferences
- PsiQuantum Revenue and Financials
- PsiQuantum Highlights
- PsiQuantum Business Model
- PsiQuantum Risk Factors
- PsiQuantum Research Report from SACRA Research
PsiQuantum Key Facts
- Multibillion-Dollar Strategic Financing & Landmark Valuation: PsiQuantum strengthened its capital position by closing a $1 billion Series E funding round led by BlackRock and Temasek, securing a $7 billion private valuation. Additionally, the company secured a proposal for a $100 million federal incentive package from the U.S. Department of Commerce under the CHIPS and Science Act alongside a $125 million contract award from the Defense Advanced Research Projects Agency (DARPA).
- Milestone Utility-Scale Site Groundbreakings & Infrastructure Expansion: PsiQuantum officially broke ground on its first two utility-scale Quantum Compute Centers in Chicago, Illinois and Moreton Bay, Queensland. Supported by an AU$940 million joint commitment from the Australian Commonwealth and Queensland state governments, these utility-scale manufacturing and cryogenic centers can position PsiQuantum ahead of pure-play quantum competitors in physical infrastructure execution.
- Technological Advancement and Patented IP: PsiQuantum continues to advance its core technology, which is based on a photonic approach that leverages standard semiconductor manufacturing. The company announced its new Omega chipset in February 2025, which is purpose-built for utility-scale quantum computing. It has also recently launched "Construct," a dedicated software suite for designing fault-tolerant quantum algorithms. This dual focus on both hardware and software, combined with its large portfolio of patents, provides a significant competitive advantage by creating a potential comprehensive, end-to-end solution for a fully fault-tolerant quantum computer.
- Strict Hardware Bottlenecks and High Capital Intensity: As PsiQuantum scales multi-hundred-million-dollar facilities, it faces steep operational exposure tied to custom silicon photonics manufacturing and complex cryogenic cooling integration. While an Australian government internal audit cleared the procedural handling of its AU$940 million public funding package, it formally classified the deal as carrying "high financial risk". Project delays, high burn rates, or hardware integration stumbles before its target operational deadlines could severely impair market confidence and liquidity.
- Pending Federal Vetting Protocols and Heightened Oversight Pressure: While federal backing provides significant capital, it can introduce stringent regulatory and operational hurdles. Following PsiQuantum's selection for the $125 million DARPA Quantum Benchmarking Initiative (QBI) Stage C tasking agreement, the company's hardware timeline is subjected to rigorous, ongoing government benchmarking and performance validation. Failure to meet these explicit third-party benchmarks or satisfy federal oversight criteria can risk stalling government disbursements and triggering severe reputation damage.
- Intensifying Competition Against Rapidly Maturing Rival Architectures: Capital expansion across the quantum sector has heightened competitive pressure, shortening the window for PsiQuantum to establish market dominance with its silicon-photonic approach. Competing fault-tolerant platforms, such as trapped-ion, neutral atom, and superconducting systems from rivals like IBM, Microsoft, and IonQ, are advancing toward commercial utility. Although PsiQuantum expanded software capabilities by integrating its Construct platform with NVIDIA CUDA-Q, failing to demonstrate a working, verified system ahead of rival architectures risks ceding key enterprise and government contracts to faster-moving market alternatives.
Trading PsiQuantum Stock
How to invest in PsiQuantum stock?
Accredited investors can buy pre-IPO stock in companies like PsiQuantum through EquityZen funds. These investments are made available by existing PsiQuantum shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell PsiQuantum stock?
Shareholders can sell their PsiQuantum stock through EquityZen's private company marketplace. EquityZen's network includes over 470K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 56K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
